Mr. Cleveland joined Avalanche as the chief executive officer and interim chief financial officer in December 2015. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm.
Our Mission
Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing therapeutic benefit to patients dealing with chronic or debilitating disease. We are leveraging our next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Our People
Print All
Mark S. Blumenkranz, MD
Co-Founder & Chairman
John P. McLaughlin
Steven D. Schwartz, MD
Paul D. Wachter
Paul B. Cleveland
Elizabeth P. Rakoczy, PhD
Chair
Jean E. Bennett, MD, PhD
Estuardo Aguilar-Cordova, MD, PhD
Thomas W. Chalberg, Jr., PhD
Mitchell H. Finer, PhD
Daniel V. Palanker, PhD